Free Trial

Zura Bio (ZURA) Stock Forecast & Price Target

Zura Bio logo
$2.39 +0.11 (+4.82%)
(As of 02:51 PM ET)

Zura Bio - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
6

Based on 7 Wall Street analysts who have issued ratings for Zura Bio in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 1 has given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for ZURA.

Consensus Price Target

$15.80
561.09% Upside
According to the 7 analysts' twelve-month price targets for Zura Bio, the average price target is $15.80. The highest price target for ZURA is $26.00, while the lowest price target for ZURA is $5.00. The average price target represents a forecasted upside of 561.09% from the current price of $2.39.
Get the Latest News and Ratings for ZURA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zura Bio and its competitors.

Sign Up

ZURA Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$15.80$15.80$15.50$16.60
Forecasted Upside561.09% Upside478.75% Upside287.50% Upside215.59% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Buy

ZURA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZURA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zura Bio Stock vs. The Competition

TypeZura BioMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside592.98% Upside25,827.31% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent ZURA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/11/2024Cantor Fitzgerald
4 of 5 stars
J. Schimmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
11/18/2024HC Wainwright
2 of 5 stars
M. Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00+58.23%
11/8/2024Chardan Capital
1 of 5 stars
 Lower TargetBuy ➝ Buy$14.00 ➝ $12.00+162.01%
11/4/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
11/4/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$15.00+242.47%
9/19/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$26.00 ➝ $26.00+514.66%
5/10/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$16.00 ➝ $21.00+344.91%
10/10/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$10.00+44.30%
8/15/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$20.00 ➝ $22.00+220.70%
6/22/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$20.00+72.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:10 PM ET.


ZURA Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Zura Bio is $15.80, with a high forecast of $26.00 and a low forecast of $5.00.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zura Bio in the last twelve months. There is currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZURA shares.

According to analysts, Zura Bio's stock has a predicted upside of 561.09% based on their 12-month stock forecasts.

Over the previous 90 days, Zura Bio's stock had 1 upgrade by analysts.

Zura Bio has been rated by research analysts at Cantor Fitzgerald, Chardan Capital, HC Wainwright, Leerink Partners, and Leerink Partnrs in the past 90 days.

Analysts like Zura Bio more than other "medical" companies. The consensus rating for Zura Bio is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZURA compares to other companies.


This page (NASDAQ:ZURA) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners